Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Merino‑Casabiel, X. (X.) | - |
dc.creator | Waller, J. (John) | - |
dc.creator | Arbizu, J. (Javier) | - |
dc.creator | García-Figueiras, R. (R.) | - |
dc.creator | González, C. (Carolina) | - |
dc.creator | Grande, E. (Enrique) | - |
dc.creator | Jiménez-Fonseca, P. (Paula) | - |
dc.creator | Sevilla, M.I. (M. I.) | - |
dc.creator | Capdevila, J. (Jaume) | - |
dc.date.accessioned | 2023-04-05T11:35:57Z | - |
dc.date.available | 2023-04-05T11:35:57Z | - |
dc.date.issued | 2018 | - |
dc.identifier.citation | Merino‑Casabiel, X. (X.); Waller, J. (John); Arbizu, J. (Javier); et al. "Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors". Clinical and translational oncology. 20 (12), 2018, 1522 - 1528 | es_ES |
dc.identifier.issn | 1699-048X | - |
dc.identifier.uri | https://hdl.handle.net/10171/65870 | - |
dc.description.abstract | Purpose Gastroenteropancreatic neuroendocrine tumors are a heterogeneous group of low incidence neoplasms characterized by a low proliferative activity and slow growth. Their response to targeted therapies is heterogeneous and often does not lead to tumor shrinkage. Thus, evaluation of the therapeutic response should difer from other kind of tumors. Methods To answer relevant questions about which techniques are best in the assessment of progression or treatment response a RAND/UCLA-based consensus process was implemented. Relevant clinical questions were listed followed by a systematic search of the literature. The expert panel answered all questions with recommendations, combining available evidence and expert opinion. Recommendations were validated through a questionnaire and a participatory meeting. Results Expert recommendations regarding imaging tools for tumor assessment and evaluation of progression were agreed upon. Available imaging techniques were reviewed and recommendations for best patient monitoring practice and the best way to evaluate treatment response were formulated. | es_ES |
dc.description.sponsorship | The development of this work has been possible thanks to the fnancial support of Novartis Oncology. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Neuroendocrine tumors | es_ES |
dc.subject | Diagnostic imaging | es_ES |
dc.subject | Nuclear medicine | es_ES |
dc.subject | Radionuclide imaging | es_ES |
dc.subject | Molecular imaging | es_ES |
dc.title | Consensus document on the progression and treatment response criteria in gastroenteropancreatic neuroendocrine tumors | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativeco mmons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. | es_ES |
dc.identifier.doi | 10.1007/s12094-018-1881-9 | - |
dadun.citation.endingPage | 1528 | es_ES |
dadun.citation.number | 12 | es_ES |
dadun.citation.publicationName | Clinical and translational oncology | es_ES |
dadun.citation.startingPage | 1522 | es_ES |
dadun.citation.volume | 20 | es_ES |
dc.identifier.pmid | 29766455 | - |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.